Innovative Therapy for SCN8A Encephalopathy and Dravet Syndrome
Introduction to Antisense Oligonucleotide Therapy
Researchers have explored a groundbreaking treatment known as antisense oligonucleotide therapy to manage the expression of a mutant SCN8A gene. This therapy has shown promise in delaying the onset of seizures and improving survival rates in mouse models of SCN8A encephalopathy and Dravet syndrome.
Understanding SCN8A Encephalopathy
SCN8A encephalopathy is classified under developmental and epileptic encephalopathies, which are rare epilepsy syndromes. They are characterized by early-onset seizures, abnormal brain electrical activity, and developmental delays or regressions in children. These conditions are often resistant to treatment and tend to worsen over time, with seizures typically appearing around four months of age.
Seizure Characteristics and Symptoms
Seizures are abrupt, uncontrolled electrical disturbances in the brain, leading to alterations in awareness, behavior, and movements. Common types of seizures include generalized tonic-clonic seizures, infantile spasms, absence seizures, and focal seizures. Additional symptoms associated with SCN8A encephalopathy may include hypotonia, movement disorders, varying degrees of intellectual disability, sleep disturbances, and features resembling autism.
Genetic Factors in SCN8A Encephalopathy
Interestingly, most individuals with SCN8A encephalopathy possess a new (de novo) mutation of the gene that was not inherited from a parent. The disorder stems from a single gain-of-function mutation that disrupts electrical activity in nerve cells. The SCN8A gene encodes a portion of the voltage-gated sodium channel protein, specifically the alpha (α8)-subunit known as Nav1.6, located at the axon initial segment of neurons. This condition is linked to DNA base-pair (missense) mutations that lead to gain-of-function disturbances.
Mechanisms of Neuronal Communication
Within the human nervous system, specialized nerve cells called neurons communicate through electrical impulses known as action potentials. These impulses are generated in one neuron and transmitted to other neurons through the release and uptake of neurotransmitters. Nav1.6 channels are present in both central nervous system nerve cells and peripheral sensory and motor neurons. These voltage-gated sodium channel proteins allow sodium ions to pass into the cell through the α-subunit pore, opening in response to voltage changes across the membrane.
Impact of SCN8A Mutations
Gain-of-function mutations in SCN8A lead to premature opening or failure to close the sodium channels, resulting in excessive electrical impulses that can cause seizures. Conversely, loss-of-function mutations may result in reduced sodium channel activity, leading to other, less severe disorders. Research has identified nine other channel genes, including SCN1A and SCN3A, with mutations contributing to a variety of disorders. In studies involving individuals with epileptic encephalopathies, de novo mutations of SCN8A were found in approximately 1% of cases.
Application of Antisense Oligonucleotide Therapy
The understanding that a gene is activated when its DNA is transcribed into RNA and then translated into proteins has led scientists to utilize antisense oligonucleotide therapy. Researchers from the University of Michigan aimed to evaluate whether they could delay seizure onset and extend survival in a mouse model of SCN8A encephalopathy by reducing the amount of mutated RNA transcript.
To achieve this, they designed an antisense oligonucleotide that would bind to both mutated and normal Scn8a transcripts, inhibiting the formation of Nav1.6 sodium channel proteins. In a study published in the Annals of Neurology, the researchers developed a conditional mouse model featuring a common de novo SCN8A mutation at amino acid number 1872 (R1872W), which affects Nav1.6 channel inactivation and leads to severe seizures.
Study Findings and Outcomes
The study produced a litter with 50% unaffected wild-type offspring and 50% SCN8A mutant mice. The mice were randomly assigned to receive either Scn8a antisense oligonucleotide treatment or a control treatment. By day 21, researchers assessed the levels of Scn8a transcript.
Results indicated that treated SCN8A mutant mice showed improved survival in a dose-dependent manner, lasting up to seven weeks. Additionally, the Scn8a ASO treatment provided protection against low-level seizure activity. In contrast, untreated mutant mice experienced sudden seizures between days 14 and 16, resulting in death within 24 hours. Notably, mutant mice receiving a second dose of Scn8a ASO at day 30 lived for approximately nine weeks, suggesting the potential for long-term treatment effects.
Researchers observed that reducing Scn8a transcript levels to about 50% of wild-type was effective in protecting against seizures, with only mild behavioral abnormalities noted. However, levels dropping below 10% of wild-type could have adverse effects. By the time seizures manifested around six weeks, Scn8a transcript levels in mutant mice had increased to levels comparable to wild-type expression. Further investigations are needed to establish the efficacy of Scn8a ASO administration post-seizure onset.
Future Prospects for Antisense Oligonucleotide Therapy
The promising results of Scn8a ASO therapy were also examined in relation to Dravet syndrome, another developmental and epileptic encephalopathy caused by mutations in the SCN1A gene. This treatment significantly increased the survival of Dravet syndrome mice from three weeks to over five months. The next phase of research will involve testing additional mouse models for seizure disorders, potentially expanding the application of targeted ASOs beyond sodium channel disorders. Notably, ASO treatment has already received approval from the US Food and Drug Administration for spinal muscular atrophy, a condition affecting motor neuron function.
Conclusion
Antisense oligonucleotide therapy represents a promising avenue for addressing childhood epilepsies, offering hope for improved management of these challenging conditions. Continued research and development could pave the way for innovative treatments targeting various genetic disorders.